After 18 years of follow-up, the cumulative probability of developing NPC was 34.6‰ for subjects seropositive for VCA/IgA and 5.4‰ for those seronegative for VCA/IgA, respectively (Figure 1). The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.